Daratumumab Improves Bone Turnover in Relapsed/Refractory Multiple Myeloma; Phase 2 Study "REBUILD"
Evangelos Terpos1, Ioannis Ntanasis-Stathopoulos1, Efstathios Kastritis1
1Department of Clinical Therapeutics, School of Medicine, National and Kapodistrian University of Athens, 11528 Athens, Greece.
Cancers
|June 10, 2022
Summary
Daratumumab treatment in multiple myeloma (MM) patients showed potential to improve bone turnover. While bone resorption markers did not significantly change, bone formation markers increased, suggesting a positive impact on bone health.
Area of Science:
- Hematology
- Oncology
- Bone Metabolism
Background:
- Multiple myeloma (MM) is a hematologic malignancy affecting bone health.
- Bone turnover markers in serum can indicate bone dynamics during MM treatment.
- Understanding the impact of novel therapies on bone remodeling is crucial.
Purpose of the Study:
- To evaluate the effect of daratumumab on bone remodeling in patients with relapsed/refractory MM.
- To assess changes in bone turnover biomarkers during daratumumab therapy.
Main Methods:
- Prospective, open-label, phase 2 study (REBUILD).
- Daratumumab administered per approved indication.
- Measured serum biomarkers of bone turnover (CTX, TRACP-5b, osteocalcin, bone-specific alkaline phosphatase, procollagen type-I N-pro-peptide, dickkopf-1, C-C motif ligand-3) at baseline and 4 months.
Main Results:
- Median changes in bone resorption markers (CTX, TRACP-5b) were not statistically significant.
- Bone formation markers (osteocalcin, bone-specific alkaline phosphatase, procollagen type-I N-pro-peptide) increased significantly.
- Dickkopf-1 and C-C motif ligand-3 levels decreased significantly, indicating reduced osteoblast inhibition.
Conclusions:
- Daratumumab therapy may positively influence bone turnover in MM patients.
- The drug appears to promote bone formation and reduce factors that inhibit osteoblasts.
- Further research is warranted to confirm these bone-related effects in MM treatment.
Related Concept Videos
Bone Remodeling
38.6K
Bone remodeling is a continuous and balanced process of bone resorption by osteoclasts and bone formation by osteoblasts. In adults, it helps maintain bone mass and calcium homeostasis. While mechanical stress can stimulate turnover as part of the normal maintenance and reparative process, several hormones also regulate bone remodeling.
38.6K
Bone Marrow Sampling and Transplants
509
Bone marrow transplant is a potential cure for several diseases, including cancer and specific genetic disorders. Notably, this procedure is applicable for patients suffering from aplastic anemia, certain types of leukemia, severe combined immunodeficiency disease (SCID), Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, thalassemia, sickle-cell disease, and certain cancers.
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy...
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy...
509
Treatment Resistant Cancers
3.4K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K
Osteoclasts in Bone Remodeling
3.2K
Osteoclasts are cells responsible for bone resorption and remodeling. They originate from hematopoietic progenitor cells present in the bone marrow. Numerous progenitor cells fuse to form multinucleated cells, each with 10-20 nuclei. A single osteoclast has a diameter of 150 to 200 µM. These cells have ruffled borders that break down the underlying bone tissue and release minerals such as calcium into the blood in bone resorption. Osteoclasts cling to bones with their ruffled edges during...
3.2K


